The China Percutaneous Coronary Intervention Market growth continues to accelerate as the country's pharmaceutical and biotechnology sectors develop novel adjunctive therapies that enhance PCI outcomes and reduce restenosis risk. With dual antiplatelet therapy optimization, PCSK9 inhibitor integration, and anti-inflammatory agents showing promise in post-PCI management, the demand for...